Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by OFI Invest Asset Management

OFI Invest Asset Management raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 26.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 381 shares of the biopharmaceutical company’s stock after purchasing an additional 79 shares during the quarter. OFI Invest Asset Management’s holdings in Alnylam Pharmaceuticals were worth $124,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ALNY. SVB Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the 1st quarter valued at about $27,000. Bessemer Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Ameritas Advisory Services LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $42,000. Washington Trust Advisors Inc. boosted its holdings in Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 61 shares during the last quarter. Finally, Larson Financial Group LLC boosted its holdings in Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 87 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 3,022 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total value of $1,364,372.56. Following the sale, the executive vice president directly owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. This represents a 13.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Tolga Tanguler sold 1,405 shares of the stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $635,130.25. Following the completion of the sale, the executive vice president directly owned 27,438 shares in the company, valued at approximately $12,403,347.90. This represents a 4.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock worth $44,160,261 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $459.66 on Monday. The firm has a market cap of $60.25 billion, a PE ratio of -186.10 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The company’s 50 day moving average is $451.37 and its two-hundred day moving average is $346.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

ALNY has been the topic of several recent analyst reports. The Goldman Sachs Group boosted their target price on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Finally, Bank of America upped their price objective on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Twenty-four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $457.16.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.